Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Year: 2020
Type: article
Abstract: Trastuzumab is life-saving but is associated with symptomatic and asymptomatic left ventricular ejection fraction (LVEF) decline. Here we report the low cardiac toxicity of a non-anthracycline and trastuzumab based treatment for patients with early stage HER2-positive breast cancer (BCA).
DOI: 10.17615/0v01-w448
Authors: Burstein, Harold J., Krop, Ian, Yardley, Denise, Shapira, Iuliana, Albain, Kathy, Marcom, Kelly, Rugo, Hope, Groarke, John, Moy, Beverly, Winer, Eric P., Najita, Julie, Dang, Chau, Moslehi, Javid, Tolaney, Sara M., Guo, Hao, Carey, Lisa A., Wolff, Antonio C., Hudis, Clifford, Miller, Kathy, Ellis, Matthew
Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon, Duke Medical Center, Loyola University Chicago, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Indiana University Indianapolis, Washington University in St. Louis, Hofstra University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Massachusetts General Hospital, Vanderbilt University, Vanderbilt University Medical Center, University of North Carolina at Chapel Hill
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2570354221